DNA methylation profiles in pneumonia patients reflect changes in cell types and pneumonia severity. Issue 12 (2nd December 2022)

• Record Type: Journal Article
• Authors: Morselli, Marco; Farrell, Colin; Montoya, Dennis; Gören, Tarık; Sabırlı, Ramazan; Türkçüer, İbrahim; Kurt, Özgür; Köseler, Aylin; Pellegrini, Matteo
• Is Part Of: Epigenetics. Volume 17:Issue 12(2022)
• Page Start: 1646
• Page End: 1660
• Publication Date: 2022-12-02
• Subjects: DNA methylation -- pneumonia -- SARS-CoV-2 -- targeted bisulfite sequencing -- cell-type deconvolution -- biomarkers; Epigenesis -- Periodicals; Epigenetica; 572.86505
• DOI: 10.1080/15592294.2022.2051862
• Languages: English
• ISSNs: 1559-2294

Abstract

ABSTRACT: Immune cell-type composition changes with age, potentially weakening the response to infectious diseases. Profiling epigenetics marks of immune cells can help us understand the relationship with disease severity. We therefore leveraged a targeted DNA methylation method to study the differences in a cohort of pneumonia patients (both COVID-19 positive and negative) and unaffected individuals from peripheral blood. This approach allowed us to predict the pneumonia diagnosis with high accuracy (AUC = 0.92), and the PCR positivity to the SARS-CoV-2 viral genome with moderate, albeit lower, accuracy (AUC = 0.77). We were also able to predict the severity of pneumonia (PORT score) with an R 2 = 0.69. By estimating immune cellular frequency from DNA methylation data, patients under the age of 65 positive to the SARS-CoV-2 genome (as revealed by PCR) showed an increase in T cells, and specifically in CD8+ cells, compared to the negative control group. Conversely, we observed a decreased frequency of neutrophils in the positive compared to the negative group. No significant difference was found in patients over the age of 65. The results suggest that this DNA methylation-based approach can be used as a cost-effective and clinically useful biomarker platform for predicting pneumonias and their severity.